Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials

SB Hanauer, U Strömberg - Clinical Gastroenterology and Hepatology, 2004 - Elsevier
Background & Aims: The aim of this study was to perform a meta-analysis of the efficacy
results from 3 placebo-controlled multicenter clinical trials of slow-release mesalamine …
被引用次数：379 相关文章

Oral pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials

SB Hanauer, U Strömberg - Clinical Gastroenterology …, 2004 - scholars.northwestern.edu
Background & Aims: The aim of this study was to perform a meta-analysis of the efficacy
results from 3 placebo-controlled multicenter clinical trials of slow-release mesalamine …

Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials

SB Hanauer, U Strömberg - Clinical Gastroenterology and Hepatology, 2004 - lup.lub.lu.se
BACKGROUND & AIMS: The aim of this study was to perform a meta-analysis of the efficacy
results from 3 placebo-controlled multicenter clinical trials of slow-release mesalamine …

[引用][C] Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials

H SB - Clin Gastroenterol Hepatol, 2004 - cir.nii.ac.jp
Oral Pentasa in the treatment of active Crohn's disease : a meta-analysis of double-blind,
placebo-controlled trials | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …

Oral pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials

SB Hanauer, U Strömberg - Clinical Gastroenterology and Hepatology, 2004 - infona.pl
Background & Aims: The aim of this study was to perform a meta-analysis of the efficacy
results from 3 placebo-controlled multicenter clinical trials of slow-release mesalamine …
[PDF] tasnimpharma.com

[PDF][PDF] Oral Pentasa in the Treatment of Active Crohn's Disease: A Meta-Analysis of Double-Blind, Placebo-Controlled Trials

SB HANAUER… - CLINICAL …, 2004 - tasnimpharma.com
Background & Aims: The aim of this study was to perform a meta-analysis of the efficacy
results from 3 placebo-controlled multicenter clinical trials of slow-release mesalamine …

Oral pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials

SB Hanauer, U Strömberg - Clinical Gastroenterology and …, 2004 - cghjournal.org
Abstract Background & Aims: The aim of this study was to perform a meta-analysis of the
efficacy results from 3 placebo-controlled multicenter clinical trials of slow-release …

Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.

SB Hanauer, U Strömberg - … : the Official Clinical Practice Journal of …, 2004 - europepmc.org
Methods Three trials fulfilled the selection criteria (double-blind, placebo-controlled,
randomized studies in adult patients treated with Pentasa 4 g/day for active Crohn's …
[HTML] nih.gov

[HTML][HTML] Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials

SB Hanauer, U Stromberg - Database of Abstracts of Reviews of …, 2004 - ncbi.nlm.nih.gov
This review compared Pentasa 4 g/day with placebo for the treatment of mild to moderate
Crohn's disease. The authors concluded that Pentasa reduced the Crohn's Disease Activity …

Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials

SB Hanauer, U Strömberg - Clinical Gastroenterology and …, 2004 - portal.research.lu.se
BACKGROUND & AIMS: The aim of this study was to perform a meta-analysis of the efficacy
results from 3 placebo-controlled multicenter clinical trials of slow-release mesalamine …